Ziopharm, Intrexon collaborate on DNA-based oncology therapeutics

Under the agreement, Ziopharm will use Intrexon’s UltraVector Technology to develop and commercialize DNA-based therapeutics.

Ziopharm will utilize Intrexon’s advanced transgene engineering platform to facilitate the controlled and precise cellular production of anti-cancer effectors.

Ziopharm will have rights to Intrexon’s complete human in vivo effector platform within the field of oncology, which includes two lead clinical-stage product candidates.

One of the product candidates is in advanced Phase I study, while the other will be subject of an Investigational New Drug (IND) filing during the first half of 2011

While Intrexon will be responsible for technology discovery efforts, managing of the patent estate, and certain aspects of manufacturing, Ziopharm will be responsible for preclinical and clinical development, other aspects of manufacturing and the commercialization.

Intrexon will acquire 12.5% of Ziopharm, and an additional 7.5% subject to certain conditions following the dosing of first patient in a US Phase II clinical trial of a product candidate created, produced or developed by Ziopharm using Intrexon technology.

In addition, subject to certain expense allocations, Ziopharm will pay Intrexon 50% of the cumulative net quarterly profits obtained from the sale of products developed from the partnership.